Indications and results of liver transplantation for Echinococcus alveolar infection: an overview

Alveolar echinococcosis (AE) of the liver, caused by the larval stage of the fox tapeworm Echinococcus multilocularis, has the characteristics of a slow-growing liver cancer. It is one of the rare parasitic diseases for which a parasitolytic drug is not yet available, and AE is lethal in the absence...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Langenbeck's archives of surgery 2003-09, Vol.388 (4), p.231-238
Hauptverfasser: Bresson-Hadni, Solange, Koch, Stéphane, Miguet, Jean-Philippe, Gillet, Michel, Mantion, Georges-André, Heyd, Bruno, Vuitton, Dominique-Angèle
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 238
container_issue 4
container_start_page 231
container_title Langenbeck's archives of surgery
container_volume 388
creator Bresson-Hadni, Solange
Koch, Stéphane
Miguet, Jean-Philippe
Gillet, Michel
Mantion, Georges-André
Heyd, Bruno
Vuitton, Dominique-Angèle
description Alveolar echinococcosis (AE) of the liver, caused by the larval stage of the fox tapeworm Echinococcus multilocularis, has the characteristics of a slow-growing liver cancer. It is one of the rare parasitic diseases for which a parasitolytic drug is not yet available, and AE is lethal in the absence of appropriate therapeutic management. Complete surgical resection of the parasite at an early stage of infection provides favourable prospects for cure, but, due to a long clinical latency, many cases are diagnosed at an advanced stage, so that partial liver resection can be performed in only 35% of patients. Benzimidazole (BZM) treatment is given in inoperable cases but these compounds are only parasitostatic, and lifelong therapy is required. During the past 20 years some centres have considered liver transplantation (LT) for the treatment of incurable AE. Our review summarizes the results of this experience based on a series of 47 European patients who received transplants between 1985 and 2002, tries to specify the real place of LT for AE, and underlines the measures that could be undertaken in the future to improve the results. Five-year survival was 71%. Five-year survival without recurrence was 58%. Major technical difficulties related either to previous laparotomies or to the loco-regional involvement were observed. The nine early deaths concerned AE patients with a long past-history of symptomatic AE (iterative cholangitis, secondary biliary cirrhosis). Five late deaths were directly related to ongoing AE, located in the brain in three cases, a very rare AE location that was not investigated before LT in these patients. In general, the pre-LT screening for distant AE metastases appeared insufficient in this series. Heavy immunosuppressive schemes, absence or delayed re-introduction of BZM after LT have clearly played a role in this unfavourable course. This unique experience indicates that, despite major technical difficulties, LT for incurable AE is feasible and could be discussed in very symptomatic cases. Before LT, interventional radiology should be preferred to repeated laparotomies. Pre-LT and post-LT BZM treatment is mandatory. A careful evaluation of possible distant metastases should be done before the decision for LT is made. After LT, the possibility of an ongoing AE must be permanently kept in mind. This could be reduced by lightening the immunosuppressants, carefully following the specific circulating antibodies, and applying a systematic
doi_str_mv 10.1007/s00423-003-0394-2
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03537140v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75697692</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-62693e38e95397e99e0753afbaafeb0e327940b12e5463cd24f7f2f93612a5483</originalsourceid><addsrcrecordid>eNpFkU1LAzEQhoMoflR_gBfJSfCwOvnaNd5EqhYKXvQc0nSCke2mJrsV_71ZW_QwzBCe92UyLyHnDK4ZQHOTASQXFUApoWXF98gxk0JVXCq2_zdLcUROcv4AgLrR8pAcMa5BgaiPiZ11y-BsH2KXqe2WNGEe2j7T6GkbNphon2yX163t-l-K-pjo1L2HLrro3FBU7QZjaxMNnUc3MnfFicYi3gT8OiUH3rYZz3Z9Qt4ep68Pz9X85Wn2cD-vnJS8r2pea4HiFrUSukGtERolrF9Y63EBKHhZHRaMo5K1cEsufeO516Jm3Cp5Kybkauv7bluzTmFl07eJNpjn-7kZ30Ao0TAJG1bYyy27TvFzwNybVcgO2_JLjEM2jap1U2teQLYFXYo5J_R_zgzMmIHZZmBKBmbMwIyai535sFjh8l-xO7r4AQ3Cgfw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75697692</pqid></control><display><type>article</type><title>Indications and results of liver transplantation for Echinococcus alveolar infection: an overview</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><creator>Bresson-Hadni, Solange ; Koch, Stéphane ; Miguet, Jean-Philippe ; Gillet, Michel ; Mantion, Georges-André ; Heyd, Bruno ; Vuitton, Dominique-Angèle</creator><creatorcontrib>Bresson-Hadni, Solange ; Koch, Stéphane ; Miguet, Jean-Philippe ; Gillet, Michel ; Mantion, Georges-André ; Heyd, Bruno ; Vuitton, Dominique-Angèle ; European group of clinicians</creatorcontrib><description>Alveolar echinococcosis (AE) of the liver, caused by the larval stage of the fox tapeworm Echinococcus multilocularis, has the characteristics of a slow-growing liver cancer. It is one of the rare parasitic diseases for which a parasitolytic drug is not yet available, and AE is lethal in the absence of appropriate therapeutic management. Complete surgical resection of the parasite at an early stage of infection provides favourable prospects for cure, but, due to a long clinical latency, many cases are diagnosed at an advanced stage, so that partial liver resection can be performed in only 35% of patients. Benzimidazole (BZM) treatment is given in inoperable cases but these compounds are only parasitostatic, and lifelong therapy is required. During the past 20 years some centres have considered liver transplantation (LT) for the treatment of incurable AE. Our review summarizes the results of this experience based on a series of 47 European patients who received transplants between 1985 and 2002, tries to specify the real place of LT for AE, and underlines the measures that could be undertaken in the future to improve the results. Five-year survival was 71%. Five-year survival without recurrence was 58%. Major technical difficulties related either to previous laparotomies or to the loco-regional involvement were observed. The nine early deaths concerned AE patients with a long past-history of symptomatic AE (iterative cholangitis, secondary biliary cirrhosis). Five late deaths were directly related to ongoing AE, located in the brain in three cases, a very rare AE location that was not investigated before LT in these patients. In general, the pre-LT screening for distant AE metastases appeared insufficient in this series. Heavy immunosuppressive schemes, absence or delayed re-introduction of BZM after LT have clearly played a role in this unfavourable course. This unique experience indicates that, despite major technical difficulties, LT for incurable AE is feasible and could be discussed in very symptomatic cases. Before LT, interventional radiology should be preferred to repeated laparotomies. Pre-LT and post-LT BZM treatment is mandatory. A careful evaluation of possible distant metastases should be done before the decision for LT is made. After LT, the possibility of an ongoing AE must be permanently kept in mind. This could be reduced by lightening the immunosuppressants, carefully following the specific circulating antibodies, and applying a systematic radiological evaluation, not only to the graft but also to the lungs and the brain.</description><identifier>ISSN: 1435-2443</identifier><identifier>EISSN: 1435-2451</identifier><identifier>DOI: 10.1007/s00423-003-0394-2</identifier><identifier>PMID: 12905036</identifier><language>eng</language><publisher>Germany: Springer Verlag</publisher><subject>Adolescent ; Adult ; Aged ; Anthelmintics ; Anthelmintics - therapeutic use ; Benzimidazoles ; Benzimidazoles - therapeutic use ; Budd-Chiari Syndrome ; Comorbidity ; Decision Trees ; Echinococcosis, Hepatic ; Echinococcosis, Hepatic - epidemiology ; Echinococcosis, Hepatic - surgery ; Ecology, environment ; Female ; Health ; Humans ; Life Sciences ; Liver Transplantation ; Male ; Middle Aged ; Retrospective Studies</subject><ispartof>Langenbeck's archives of surgery, 2003-09, Vol.388 (4), p.231-238</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-62693e38e95397e99e0753afbaafeb0e327940b12e5463cd24f7f2f93612a5483</citedby><orcidid>0000-0003-1258-4050</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12905036$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-fcomte.hal.science/hal-03537140$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Bresson-Hadni, Solange</creatorcontrib><creatorcontrib>Koch, Stéphane</creatorcontrib><creatorcontrib>Miguet, Jean-Philippe</creatorcontrib><creatorcontrib>Gillet, Michel</creatorcontrib><creatorcontrib>Mantion, Georges-André</creatorcontrib><creatorcontrib>Heyd, Bruno</creatorcontrib><creatorcontrib>Vuitton, Dominique-Angèle</creatorcontrib><creatorcontrib>European group of clinicians</creatorcontrib><title>Indications and results of liver transplantation for Echinococcus alveolar infection: an overview</title><title>Langenbeck's archives of surgery</title><addtitle>Langenbecks Arch Surg</addtitle><description>Alveolar echinococcosis (AE) of the liver, caused by the larval stage of the fox tapeworm Echinococcus multilocularis, has the characteristics of a slow-growing liver cancer. It is one of the rare parasitic diseases for which a parasitolytic drug is not yet available, and AE is lethal in the absence of appropriate therapeutic management. Complete surgical resection of the parasite at an early stage of infection provides favourable prospects for cure, but, due to a long clinical latency, many cases are diagnosed at an advanced stage, so that partial liver resection can be performed in only 35% of patients. Benzimidazole (BZM) treatment is given in inoperable cases but these compounds are only parasitostatic, and lifelong therapy is required. During the past 20 years some centres have considered liver transplantation (LT) for the treatment of incurable AE. Our review summarizes the results of this experience based on a series of 47 European patients who received transplants between 1985 and 2002, tries to specify the real place of LT for AE, and underlines the measures that could be undertaken in the future to improve the results. Five-year survival was 71%. Five-year survival without recurrence was 58%. Major technical difficulties related either to previous laparotomies or to the loco-regional involvement were observed. The nine early deaths concerned AE patients with a long past-history of symptomatic AE (iterative cholangitis, secondary biliary cirrhosis). Five late deaths were directly related to ongoing AE, located in the brain in three cases, a very rare AE location that was not investigated before LT in these patients. In general, the pre-LT screening for distant AE metastases appeared insufficient in this series. Heavy immunosuppressive schemes, absence or delayed re-introduction of BZM after LT have clearly played a role in this unfavourable course. This unique experience indicates that, despite major technical difficulties, LT for incurable AE is feasible and could be discussed in very symptomatic cases. Before LT, interventional radiology should be preferred to repeated laparotomies. Pre-LT and post-LT BZM treatment is mandatory. A careful evaluation of possible distant metastases should be done before the decision for LT is made. After LT, the possibility of an ongoing AE must be permanently kept in mind. This could be reduced by lightening the immunosuppressants, carefully following the specific circulating antibodies, and applying a systematic radiological evaluation, not only to the graft but also to the lungs and the brain.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anthelmintics</subject><subject>Anthelmintics - therapeutic use</subject><subject>Benzimidazoles</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Budd-Chiari Syndrome</subject><subject>Comorbidity</subject><subject>Decision Trees</subject><subject>Echinococcosis, Hepatic</subject><subject>Echinococcosis, Hepatic - epidemiology</subject><subject>Echinococcosis, Hepatic - surgery</subject><subject>Ecology, environment</subject><subject>Female</subject><subject>Health</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Liver Transplantation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><issn>1435-2443</issn><issn>1435-2451</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1LAzEQhoMoflR_gBfJSfCwOvnaNd5EqhYKXvQc0nSCke2mJrsV_71ZW_QwzBCe92UyLyHnDK4ZQHOTASQXFUApoWXF98gxk0JVXCq2_zdLcUROcv4AgLrR8pAcMa5BgaiPiZ11y-BsH2KXqe2WNGEe2j7T6GkbNphon2yX163t-l-K-pjo1L2HLrro3FBU7QZjaxMNnUc3MnfFicYi3gT8OiUH3rYZz3Z9Qt4ep68Pz9X85Wn2cD-vnJS8r2pea4HiFrUSukGtERolrF9Y63EBKHhZHRaMo5K1cEsufeO516Jm3Cp5Kybkauv7bluzTmFl07eJNpjn-7kZ30Ao0TAJG1bYyy27TvFzwNybVcgO2_JLjEM2jap1U2teQLYFXYo5J_R_zgzMmIHZZmBKBmbMwIyai535sFjh8l-xO7r4AQ3Cgfw</recordid><startdate>200309</startdate><enddate>200309</enddate><creator>Bresson-Hadni, Solange</creator><creator>Koch, Stéphane</creator><creator>Miguet, Jean-Philippe</creator><creator>Gillet, Michel</creator><creator>Mantion, Georges-André</creator><creator>Heyd, Bruno</creator><creator>Vuitton, Dominique-Angèle</creator><general>Springer Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-1258-4050</orcidid></search><sort><creationdate>200309</creationdate><title>Indications and results of liver transplantation for Echinococcus alveolar infection: an overview</title><author>Bresson-Hadni, Solange ; Koch, Stéphane ; Miguet, Jean-Philippe ; Gillet, Michel ; Mantion, Georges-André ; Heyd, Bruno ; Vuitton, Dominique-Angèle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-62693e38e95397e99e0753afbaafeb0e327940b12e5463cd24f7f2f93612a5483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anthelmintics</topic><topic>Anthelmintics - therapeutic use</topic><topic>Benzimidazoles</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Budd-Chiari Syndrome</topic><topic>Comorbidity</topic><topic>Decision Trees</topic><topic>Echinococcosis, Hepatic</topic><topic>Echinococcosis, Hepatic - epidemiology</topic><topic>Echinococcosis, Hepatic - surgery</topic><topic>Ecology, environment</topic><topic>Female</topic><topic>Health</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Liver Transplantation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bresson-Hadni, Solange</creatorcontrib><creatorcontrib>Koch, Stéphane</creatorcontrib><creatorcontrib>Miguet, Jean-Philippe</creatorcontrib><creatorcontrib>Gillet, Michel</creatorcontrib><creatorcontrib>Mantion, Georges-André</creatorcontrib><creatorcontrib>Heyd, Bruno</creatorcontrib><creatorcontrib>Vuitton, Dominique-Angèle</creatorcontrib><creatorcontrib>European group of clinicians</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Langenbeck's archives of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bresson-Hadni, Solange</au><au>Koch, Stéphane</au><au>Miguet, Jean-Philippe</au><au>Gillet, Michel</au><au>Mantion, Georges-André</au><au>Heyd, Bruno</au><au>Vuitton, Dominique-Angèle</au><aucorp>European group of clinicians</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Indications and results of liver transplantation for Echinococcus alveolar infection: an overview</atitle><jtitle>Langenbeck's archives of surgery</jtitle><addtitle>Langenbecks Arch Surg</addtitle><date>2003-09</date><risdate>2003</risdate><volume>388</volume><issue>4</issue><spage>231</spage><epage>238</epage><pages>231-238</pages><issn>1435-2443</issn><eissn>1435-2451</eissn><abstract>Alveolar echinococcosis (AE) of the liver, caused by the larval stage of the fox tapeworm Echinococcus multilocularis, has the characteristics of a slow-growing liver cancer. It is one of the rare parasitic diseases for which a parasitolytic drug is not yet available, and AE is lethal in the absence of appropriate therapeutic management. Complete surgical resection of the parasite at an early stage of infection provides favourable prospects for cure, but, due to a long clinical latency, many cases are diagnosed at an advanced stage, so that partial liver resection can be performed in only 35% of patients. Benzimidazole (BZM) treatment is given in inoperable cases but these compounds are only parasitostatic, and lifelong therapy is required. During the past 20 years some centres have considered liver transplantation (LT) for the treatment of incurable AE. Our review summarizes the results of this experience based on a series of 47 European patients who received transplants between 1985 and 2002, tries to specify the real place of LT for AE, and underlines the measures that could be undertaken in the future to improve the results. Five-year survival was 71%. Five-year survival without recurrence was 58%. Major technical difficulties related either to previous laparotomies or to the loco-regional involvement were observed. The nine early deaths concerned AE patients with a long past-history of symptomatic AE (iterative cholangitis, secondary biliary cirrhosis). Five late deaths were directly related to ongoing AE, located in the brain in three cases, a very rare AE location that was not investigated before LT in these patients. In general, the pre-LT screening for distant AE metastases appeared insufficient in this series. Heavy immunosuppressive schemes, absence or delayed re-introduction of BZM after LT have clearly played a role in this unfavourable course. This unique experience indicates that, despite major technical difficulties, LT for incurable AE is feasible and could be discussed in very symptomatic cases. Before LT, interventional radiology should be preferred to repeated laparotomies. Pre-LT and post-LT BZM treatment is mandatory. A careful evaluation of possible distant metastases should be done before the decision for LT is made. After LT, the possibility of an ongoing AE must be permanently kept in mind. This could be reduced by lightening the immunosuppressants, carefully following the specific circulating antibodies, and applying a systematic radiological evaluation, not only to the graft but also to the lungs and the brain.</abstract><cop>Germany</cop><pub>Springer Verlag</pub><pmid>12905036</pmid><doi>10.1007/s00423-003-0394-2</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1258-4050</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1435-2443
ispartof Langenbeck's archives of surgery, 2003-09, Vol.388 (4), p.231-238
issn 1435-2443
1435-2451
language eng
recordid cdi_hal_primary_oai_HAL_hal_03537140v1
source MEDLINE; Springer Online Journals Complete
subjects Adolescent
Adult
Aged
Anthelmintics
Anthelmintics - therapeutic use
Benzimidazoles
Benzimidazoles - therapeutic use
Budd-Chiari Syndrome
Comorbidity
Decision Trees
Echinococcosis, Hepatic
Echinococcosis, Hepatic - epidemiology
Echinococcosis, Hepatic - surgery
Ecology, environment
Female
Health
Humans
Life Sciences
Liver Transplantation
Male
Middle Aged
Retrospective Studies
title Indications and results of liver transplantation for Echinococcus alveolar infection: an overview
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T23%3A02%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Indications%20and%20results%20of%20liver%20transplantation%20for%20Echinococcus%20alveolar%20infection:%20an%20overview&rft.jtitle=Langenbeck's%20archives%20of%20surgery&rft.au=Bresson-Hadni,%20Solange&rft.aucorp=European%20group%20of%20clinicians&rft.date=2003-09&rft.volume=388&rft.issue=4&rft.spage=231&rft.epage=238&rft.pages=231-238&rft.issn=1435-2443&rft.eissn=1435-2451&rft_id=info:doi/10.1007/s00423-003-0394-2&rft_dat=%3Cproquest_hal_p%3E75697692%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75697692&rft_id=info:pmid/12905036&rfr_iscdi=true